Navigation Links
BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
Date:8/5/2013

al of skin lesions has completed a Phase 1/2 study; BL-7040 for treating inflammatory bowel disease (IBD) has completed a Phase 2a trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has commenced a Phase 2 study; BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study; BL-1021 for neuropathic pain is in Phase 1 development; and BL-1020 for schizophrenia. In addition, BioLineRx has five products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase 3) and commercialization. For more information on BioLineRx, please visit www.biolinerx.com, the content of which does not form a part of this press release.

Various statements in this release concerning BioLineRx's future expectations, including specifically those related to the development and commercialization of BL-8040, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking stateme
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (NYSE: DGX ) today announced that Stephen ... President and Chief Executive Officer, effective May 1, 2012. ... 30 to ensure a smooth leadership transition. Mr. Rusckowski ... Directors.  (Photo: http://photos.prnewswire.com/prnh/20120411/NY85952 ) ...
... Lilly and Company (NYSE: LLY ) will announce ... Wednesday, April 25, 2012.  Lilly will also conduct a conference ... to further detail the company,s financial performance. ... 10:00 a.m. EDT.  Investors, media and the general public can ...
Cached Medicine Technology:Quest Diagnostics Names Steve Rusckowski as President and CEO 2Quest Diagnostics Names Steve Rusckowski as President and CEO 3
(Date:4/18/2014)... it make you feel? According to psychologists, remembering the ... how sad you were or how embarrassed you felt, ... stop thinking about it. , When these negative ... memories, rather than how you felt, is a relatively ... of these memories, a new study suggests. , Researchers ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... for disease,research got a boost Friday night as Chrysler ... Suwichada presided as honorary chairs for,the Juvenile Diabetes Research ... As part of the evening,s activities, the Jane Jospey ... Ford II. The award is given each year,to individuals ...
... Women to ,Speak Up For Down There, During National ... ... Despite living in a society,that promotes images and icons of female ... Sue Johannsen and even,former Supreme Court Justice Sandra Day O,Conner, more ...
... tough. The good news: it gets better. , A ... its graduates (ages 20-29 years old) tracked mental health ... at how key events like leaving home and becoming ... showed a significant decrease in depressive symptoms over the ...
... May 13, 2008 The American Society ... control guidelines regarding gastrointestinal (GI) endoscopy. The guidelines ... event since the adoption of endoscope reprocessing (cleaning) ... the May issue of GIE: Gastrointestinal Endoscopy, the ...
... division is essential to life, but the mechanism by ... genetic endowments is little understood. In a new study, ... report on how a key motor protein orchestrates chromosome ... The study appeared in the Proceedings of the National ...
... of childhood,obesity in America has more than tripled ... ages 10 to 17 are overweight or obese(2).,Compelled ... obesity epidemic for,children, families, communities and the health ... ( http://www.bluefoundationfl.com ), the,philanthropic affiliate of Blue Cross ...
Cached Medicine News:Health News:Chrysler LLC Vice Chairman and President Jim Press and His Wife Suwichada Serve as Honorary Co-Chairs of Annual Juvenile Diabetes Research Foundation Promise Ball 2Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 2Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 3Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 4Health News:Depression and anger can plague recent university graduates: Study 2Health News:ASGE issues updated infection control guidelines for gastrointestinal endoscopy 2Health News:ASGE issues updated infection control guidelines for gastrointestinal endoscopy 3Health News:Research shines spotlight on a key player in the dance of chromosomes 2Health News:Research shines spotlight on a key player in the dance of chromosomes 3Health News:The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: